Krystal Biotech Reports Topline Results from GEM-3 Trial
Krystal Biotech, Inc. (NASDAQ: KRYS) has reported topline results from its GEM-3 trial, investigating beremagene geperpavec, as known as VYJUVEK for treatment of dystrophic Epidermolysis Bullosa. The primary endpoint of the trial evaluated total wound healing of topical VYJUVEK compared...